Uric acid in Parkinson's disease.
Identifieur interne : 002004 ( PubMed/Checkpoint ); précédent : 002003; suivant : 002005Uric acid in Parkinson's disease.
Auteurs : Ilana Schlesinger [Israël] ; Naomi SchlesingerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Uric Acid.
- chemical , therapeutic use : Antioxidants, Uric Acid.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD.
DOI: 10.1002/mds.22139
PubMed: 18618666
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18618666Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease.</title><author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.22139</idno><idno type="RBID">pubmed:18618666</idno><idno type="pmid">18618666</idno><idno type="wicri:Area/PubMed/Corpus">002155</idno><idno type="wicri:Area/PubMed/Curation">002155</idno><idno type="wicri:Area/PubMed/Checkpoint">002004</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Uric acid in Parkinson's disease.</title><author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidants (therapeutic use)</term><term>Humans</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Uric Acid (blood)</term><term>Uric Acid (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Uric Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term><term>Uric Acid</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18618666</PMID><DateCreated><Year>2008</Year><Month>10</Month><Day>02</Day></DateCreated><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2008</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Uric acid in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1653-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22139</ELocationID><Abstract><AbstractText>Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD.</AbstractText><CopyrightInformation>(c) 2007 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schlesinger</LastName><ForeName>Ilana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlesinger</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014527">Uric Acid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22139</ArticleId><ArticleId IdType="pubmed">18618666</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name></noCountry><country name="Israël"><noRegion><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18618666
|texte= Uric acid in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18618666" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |